the eu market for bioanalysis
DESCRIPTION
Bioanalytical market, bioanalysis, pharmaceutical development, contract servicesTRANSCRIPT
Summary Report – October 2003
PARIOFORMA LTD 55 Princes Gate Exhibition Road London SW7 2PN United Kingdom Tel: +44 (0) 20 7225 3538 www.parioforma.com
PARIOFORMA
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
The European pharmaceutical industry invested 18.9 billion Euros in R&D in 2001, and was projected to spend 19.8 billion Euros in 2002.
This sum covers all R&D spending within EFPIA countries by national and foreign companies.
However, despite increasing R&D spending in Europe it should be noted that Europe is gradually losing ground to the US as a locus of innovation. Between 1990 and 2002, R&D investment in United States rose more than fivefold, while in Europe it only grew 2.5 times.
FIGURE
PHARMACEUTICAL R&D EXPENDITURE IN EUROPE AND USA
0
5000
10000
15000
20000
25000
30000
35000
1990 2000 2001 2002e
Millio
ns
Eu
ros
US
EU
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
0
1000
2000
3000
4000
5000
6000
Belg
ium
Den
mark
Fin
lan
d
Fra
nce
Germ
an
y
Irela
nd
Italy
Neth
erl
an
ds
No
rway
Sp
ain
Sw
ed
en
Sw
itzerl
an
d UK
Eu
ros M
illi
on
s
1999 2000 2001
Amount spent in each country by national and foreign companies
FIGURE 2
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
97
90
68
52
66
77
63 61
29
5 6 4
0
20
40
60
80
100
120
1988-1992 1993-1997 1998-2002
Nu
mb
er
of
ch
em
ica
l e
nti
tie
s
Europe
United States
Japan
Others
By location of mother company
FIGURE 3
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
A major driving force behind the growth of the European Biotech industry was the flow of money into dedicated mutual funds in the latter part of the 1990’s up until 2000.
In addition, countries such as The Netherlands and Germany were at the forefront of integrating state and private capital to support the life sciences industry – this had the effecting of initiating many new Biotech start-ups, notably in Germany who still lead Europe in terms of the number of companies – see figure 4.
However, the impressive stock performances witnessed by European companies over this period was not sustainable. After a decade of 30-40% year on year growth in revenues, the European biotech sector stalled in 2002.
The UK remains the dominant player with 43% of total market capitalization (€9.4 billion) and 37% (€2.9 billion) of revenues.
The current hostile financing environment is forcing companies to radically rethink their strategies, and further fall-out in the sector can be expected over the coming twelve months. However this is a cycle that has been experienced several times already in the US and will result in a stronger and more robust industry in Europe.
However, it should be noted that the number of profitable biotech companies is increasing and the average loss per public company has halved over the past 4 years to €7 million.
Europe's public biotech companies now have 53 products in phase III clinical trials. Hence despite the harsh environment companies are continuing to develop innovative products and a potential tidal wave of product successes is building up, which could transform the industry.
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
347
285
233
170147
124
82 75 70 6850
33 18
13
46
32
1513
5
2
9
6
1
0
50
100
150
200
250
300
350
400
Ge
rma
ny
UK
Fra
nc
e
Sw
ed
en
Isra
el
Sw
itze
rla
nd
Ne
the
rla
nd
s
Fin
lan
d
De
nm
ark
Be
lgiu
m
Ita
ly
Ire
lan
d
No
rwa
y
Nu
mb
er
of
Co
mp
an
ies
Private Public
FIGURE 4
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
UK
Sw
itzerl
an
d
Neth
erl
an
ds
Irela
nd
Fra
nce
Germ
an
y
Revenues
Industry market capitalisation
0
1
2
3
4
5
6
7
8
9
10
Billio
ns
Eu
ros
Source: Ernst & Young
FIGURE 5
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
0
50
100
150
200
250
300
350
400
450
500
2000 2001 2002e 2003e 2004e 2005e
Millio
ns
Eu
ros
US
EU
Source: RM Consulting, published data PhRMA, E & Y, Scrip, Pharmaceutical Compendium: CMR International
FIGURE 7
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
Figure 7 depicts the market forecasts for the North American and European bioanalytical market – development and discovery support.
It shows modest, but sustained growth over the next few years; however, calculations assumed a constant US vs. EU split of R&D expenditure over this period1. Given the current trend towards the US as a locus of innovation; figures might be biased slightly more in favour of the US over time.
Market analysis revealed that the key drivers for market value are:
◦ the volume of new business arising, due to new candidates entering development – there are an average 3,405 drugs2 in active trials worldwide with an estimated 1,362 candidates in trials3 in Europe;
◦ increased outsourced volumes from medium sized Pharma and Biotechs – these companies are traditional outsourcers;
◦ higher sample prices for increased complexity of biomolecule assays;
◦ increased range of possible assays at premium prices – biomarkers, metabolite profiling, etc.
The underlying market growth rate is positive - bioanalysis remains an attractive business.
1 The R&D split for the year 2001 (EFPIA, PhRMA- Pharmaceutical R&D Expenditure in Europe and the USA): Europe: 41%; USA : 59%.
2 Average number of Adis R&D Insight; IMS R&D Focus; Pharmaprojects.
3 RM estimate based on the ratio of new entities by geographical region.
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
Bioanalytical buying behaviour can be viewed as a factor of company size, company “attitude” and the stage of development.
“Attitude,” or the propensity to outsource, is both a function of company size and company culture. Geographical location impacts on a company’s social, cultural and economic heritages.
Analysis of the European bioanalytical market highlighted some geographical trends:
◦ Particularly in continental Europe there can be very significant “social” costs that a company must pay for each employee; it is also a highly regulated employment market – this combined with low cost labor market gives rise to the tendency for more to be done in-house in parts of continental Europe than in the US;
◦ There is a trend to use European phase I units (notably in the UK) to avoid regulatory IND submissions – however, phase II often returns to the US in preparation for FDA registration;
◦ Within Europe, the issue of language barriers can add further complexity, people preferring to deal with a service supplier in their mother-tongue. There is also the concept of keeping work within national boundaries – e.g. French companies prefer to deal with French vendors;
◦ Additionally, the buying process tends to be more formalized for US based companies who have well developed procurement procedures – such processes tend to be more embryonic for European based pharmacos.
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
Market research indicates that the European bioanalytical business lags behind the US by as much as two years in terms of market development.
The European business is also far more fragmented than in North America and is characterized by:
◦ several new entrants in last 2 years – e.g. York Bioanalysis, Xendo Labs;
◦ a great many small labs with 3 – 6 LC/MS machines;
◦ “stand-alone” labs, as opposed to full service CROs, offering a suite of bioanalytical services including LC-MS/MS and immunoassays;
◦ no dominant player – MDS, unlike in the US, is not a strong player.
The competitive situation in Europe is not as intense as in the US, and most labs are predicting growth in middle and upper teens.
This is because they are not yet under the same degree of price pressure as in the US; in part because their prices are already much lower1, but also because “mid-sized” European Pharma companies have continued to maintain or grow their outsourcing in contrast to US “Big Pharma”.
European Pharma companies also feel that they are getting “good value” from the contract labs and are less concerned about price than their US counterparts.
1 See Appendix
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
The bioanalytical lab market currently shows no signs of concentrating, with no “lab-lab” mergers. Instead the trend has been to acquire or merge with complementary organisations e.g. PPDI + MRLI, Inveresk + ClinTrials, Icon + Medeval, AAI + MTRA; Cephac + ITEC Pharmacology; or for new entrants to buy their way in e.g. Parexel + CEMAF.
These “complimentary” mergers link the bioanalytical services of one company to the clinical services of another with the aim of improving business lead generation and more importantly the continuity of business from one phase to another.
Europe has also been the focus for expansion for many US labs – the UK in particular, for example:
◦ ABC Laboratories – N. Ireland (now acquired by CSS Analytical);
◦ Advion Biosciences – Norwich, England;
◦ BAS – Congleton, England;
◦ BioReliance – Scotland;
◦ CentaLabs – Cambs; England.
Other well-known bioanalytical names in Europe include:
◦ Covance – Harrogate, England;
◦ AAI – Neu-Ulm, Germany;
◦ MDS – Zurich, Switzerland;
◦ Quintiles – Scotland, Sweden;
◦ Inveresk – Scotland;
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
Despite the trend towards the US as a locus of innovation, Europe still exhibits healthy growth in terms of R&D spending – see figure 1.
In the past 5 years, Europe in particular has experienced vigorous M&A activity in the pharmaceutical industry. A consequence of this has been much pipeline pruning with delays, postponements and even cancellations in clinical programs. The effects of this are still being felt - see figure 3.
However, worldwide drug pipelines are healthy with an estimated 1,362 candidates in active clinical trials in Europe, including 53 products in phase III originating from Europe's public biotech companies.
Europe can be divided into bioanalytical “hotspots” according to R&D spending – see figure 2:
1. UK;
2. Germany;
3. France;
4. Switzerland;
5. Scandinavia – Norway, Finland, Sweden, Denmark;
6. Benelux – The Netherlands, Belgium;
7. Italy;
8. Spain.
Decreasing
attractiveness
on the basis of
R&D spending
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
Germany still leads in Europe in terms of the number of Biotech companies – see figure 4. However, there is a widening divide in terms of revenues and market capitalisation – see figure 5.
The UK remains the dominant Biotech player and therefore, provides the most attractive opportunity from a bioanalytical perspective. Not only are there a large number of Biotech companies themselves, but revenues are stronger – these companies are more likely to be able to afford and maintain clinical programs.
This report would not be complete without mentioning the fact that Europe has a very mature generics industry that is facing a period of unprecedented growth - $82 billion worth of global blockbusters are set to face US patent expiry by 2007.
Rising competition from Indian and Eastern European low cost generic providers will augment the pressure on margins, forcing Western players to add value through specialty generics and super generics.
For some labs the generic market is an attractive business; but unlike the “research business” this area is highly price sensitive - prospective customers “shop around” for the cheapest option. It is particularly suitable for high volume players who can easily amortise the cost of assay development.
Entering this market can require considerable investment. Proprietary assays are usually owned by the original customer, consequently a lab has to re-develop and validate an assay before it can claim ownership and sell on to a generics customer.
The economics of the business suggest that it takes 2 – 3 customers to break into profit per assay developed.
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
Summary of Opportunities
United Kingdom
Germany
Switzerland
All three countries present an attractive opportunity for a bioanalytical business.
The United Kingdom because it remains the main focus of R&D spending in Europe and
continues to outpace the rest of Europe in this respect. It has the highest number of R&D
bases and the most profitable Biotech industry in Europe. Employment laws are more
favourable in the UK than in continental Europe; however, sales of a UK-based facility could
be vulnerable to exchange rate fluctuations.
Germany is also attractive from an R&D point of view. AAI is the dominant player and there
are a number of local players – Germany has not been the focus of expansion for US-based
labs as has the UK. Germany also leads Europe in the size and maturity of its generics
industry.
For its size, Switzerland has a high density of R&D based companies and a high level of
R&D spending. MDS is present but not dominant, and there are a number of well-
established local players.
A lab situated in either Germany or Switzerland is also well placed from a geographical point
of view to serve customers in other parts of continental Europe.
France
Attractive from an R&D spending point of view; but this market is heavily dominated by Aster
Cephac and Parexel. Aside from these large players there are only a handful of smaller local
players.
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
Summary of Opportunities
Scandinavia –
Norway, Sweden,
Finland and
Denmark
Sweden and Denmark dominate in terms of R&D spending.
The region supports a large number of Biotech companies, led by Sweden, but Biotech
revenues are very low in comparison to other countries in Europe.
In terms of suppliers, Quintiles has a small facility attached to a Phase I unit in Sweden – but
this is not well advertised. There are a few local suppliers, again mainly in Sweden, and
many sponsor companies traditionally outsource to other regions of Europe.
Sales from a lab in this region would also be vulnerable to fluctuations in exchange rates. It
is probably not an area that would attract bioanalytical business from other parts of Europe.
Benelux – The
Netherlands and
Belgium
Already many low cost labs present notably in The Netherlands where government
investment helped initiate start ups in the life science sector.
Many technical graduates at low cost and a highly regulated employment market – hence
many R&D based companies find it more cost effective to conduct work in-house rather than
to outsource.
Southern Europe –
Italy & Spain
Sponsor firms either conduct in-house bioanalysis or outsource to Northern European
companies. Some very small local labs only.
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
Summary of Opportunities
CEE
The Czech and Slovak Republics, the Baltics, Poland, Hungary, and Slovenia will all be part
of Europe as of May 2004.
The domestic pharmaceutical industry in this region is dominated by the cheap local
production of generic drugs. R&D bases of Western firms tend to conduct work in-house due
to the low cost of skilled labor as well as outsourcing to Western European companies.
The CEE is now fast becoming the preferred location for many clinical trials due to the
relatively lower costs per patient (in comparison to Western Europe) as well as the need to
access treatment naive patients.
A lab in this region [e.g. Czech Republic] could leverage the cheap skills base and the ease
of communication with the rest of Europe. There are at present, no well known bioanalytical
names in this region.
PARIOFORMA
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
GEOGRAPHY Mid 1990s (US $) 2002 (US$) 2004/2005 US$
USA} Average for Standard Assay $130 $70 $40
USA } Range for Standard Assay $100 - 150 $60 - 80 $30 - 40
Europe} Average for Standard
Assay $90 $63 $50
Europe} Range for Standard
Assay $84 - $98 $50 - 90 -
Source: RM estimates and analysis
PARIOFORMA
LONDON OFFICE ASSOCIATE OFFICES
Charles Rowlands Senior Partner 55 Prince’s Gate Exhibition Road London SW7 2PN United Kingdom Tel: +44 (0) 7803 907577 www.parioforma.com
USA Intrix Corp, Darien Connecticut
Eastern Europe
IMRP, Moscow
Brazil Intrix Corp, São Paulo
Japan TRN, Tokyo
Parioforma Ltd – 55 Princes Gate – London SW7 2PN – United Kingdom
www.parioforma.com
RM Consulting is now part of Parioforma Ltd., an independent business consultancy headquartered in London, UK. Key benefits of working with Parioforma: Bespoke studies – tailored to client needs and
timelines.
Affordable research prices – makes your budgets go further.
High quality research – experienced science-based team, all with post-graduate science and/ or MBA qualifications and with 10-25+ years experience in Life Science and High Technology industries.
Unique problem solving approach – the team is highly specialised, but diverse in experience and background, enabling analysis of problems from different perspectives.
Strategic Pointers – helps clients better understand the research and implications for their business.
Practical implementable solutions – not just “over-clever analysis.”
Our knowledge is extensive and experience broad – please visit our website for a full listing of all our services.
Please don't hesitate to contact us for an informal discussion – either by telephone on +44 (0) 207 225 3538 or by email at: [email protected]